表紙
市場調查報告書
商品編碼
1076443

抗體受託製造的全球市場 - 市場規模、佔有率、趨勢分析:各產品(單株抗體,多株抗體,其他),各來源,各最終用途,各地區,各市場區隔的預測(2022年∼2030年)

Antibodies Contract Manufacturing Market Size, Share & Trends Analysis Report, By Product (Monoclonal Antibodies, Polyclonal Antibodies, Others), By Source, By End Use, By Region, And Segment Forecasts, 2022 - 2030

出版日期: | 出版商: Grand View Research, Inc. | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球抗體受託製造的市場規模,預計至2030年達到359億美元,2022年∼2030年預計以13.1%的年複合成長率成長。

治療用抗體的生產的需求高漲,成為促進在預測期間內的市場成長的主要原因。還有主要企業的抗體生產的研究開發預算劇增,也推動市場成長。

本報告提供全球抗體受託製造市場相關調查分析,市場趨勢,各產品、來源、最終用途、地區的分析,競爭情形等資訊。

目錄

第1章 調查手法和範圍

第2章 摘要整理

第3章 抗體受託製造市場變數、趨勢、範圍

  • 滲透與成長預測的製圖
  • 產業的價值鏈分析
  • 市場動態
  • 抗體受託製造市場分析工具

第4章 抗體受託製造市場:估計趨勢分析,各產品

  • 市場區隔儀表板
  • 定義和範圍
  • 抗體受託製造市場佔有率(2021年、2030年)
  • 市場規模、預測、趨勢分析(2017年∼2030年)
    • 單株抗體
    • 多株抗體
    • 其他

第5章 抗體受託製造市場:估計趨勢分析,各來源

  • 市場區隔儀表板
  • 定義和範圍
  • 抗體受託製造市場佔有率(2021年、2030年)
  • 市場規模、預測、趨勢分析(2017年∼2030年)
    • 哺乳類
    • 微生物

第6章 抗體受託製造市場:估計趨勢分析,各最終用途

  • 市場區隔儀表板
  • 定義和範圍
  • 抗體受託製造市場佔有率(2021年、2030年)
  • 市場規模、預測、趨勢分析(2017年∼2030年)
    • 生物製藥企業
    • 研究所
    • 其他

第7章 抗體受託製造市場:估計趨勢分析,各地區

  • 地區市場儀表板
  • 地區市場佔有率分析(2021年、2030年)
  • 地區市場佔有率(2020年)
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
  • 南美
    • 巴西
    • 阿根廷
    • 墨西哥
    • 哥倫比亞
    • 智利
  • 中東、非洲
    • 南非
    • 阿拉伯聯合大公國
    • 埃及

第8章 競爭情形

  • 最近的趨勢及影響分析:主要的各打入市場業者
目錄
Product Code: GVR-4-68039-920-3

Antibodies Contract Manufacturing Market Growth & Trends:

The global antibodies contract manufacturing market is expected to reach USD 35.9 billion by 2030, registering a CAGR of 13.1% from 2022 to 2030, according to a new report by Grand View Research, Inc. Rise in demand for the production of therapeutic antibodies is the main factor that will drive the growth of the market during the forecast period. Antibodies are the leading biopharmaceutical products that precisely target abnormal cells. Thus, many biopharmaceutical companies have begun to focus on the development of advanced antibodies for the treatment of chronic diseases such as cancer, arthritis, and rheumatic heart disease. The impact of COVID-19 has boosted the market growth, with the application of monoclonal antibodies therapy used as a treatment for COVID-19 patients.

A surge in the R&D budget for the production of antibodies by key players is also driving the growth of the market. For the ongoing fight against COVID-19, Monoclonal antibody (mAb) therapy is proven to be an effective treatment. The aim of this treatment is to prevent hospitalizations, decrease viral loads, and minimize symptom severity.

During the coronavirus outburst, the supply chain of biopharmaceutical companies remained robust and was largely unaffected worldwide. Similarly, antibody contract manufacturers are observing a rise in demand for the production of antibodies that will be used for treatments related to the COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the antibody contract manufacturing market. For instance, in December 2021, an agreement was formed between Samsung Biologics and AstraZeneca to manufacture Evusheld, which is an amalgamation of binary antibodies in development for the potential treatment of COVID-19.

The growth of CMOs is greatly dependent on favorable opportunities offered by the biopharmaceutical industry. Expansion and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2022, FUJIFILM Diosynth Biotechnologies announced an expansion in North Carolina; with this expansion, the company will increase skilled positions including researchers and scientists by 2024 to generate strong commercial processes

Antibodies Contract Manufacturing Market Report Highlights:

  • Monoclonal antibodies-based antibody contract manufacturing captured the largest market share about 70.9% in 2021, owing to the high penetration of mammalian expression systems for biologics development
  • Based on the source offered in this market, the mammalian segment contributed the largest share of 58.5% in 2021, as they are considered a more reliable, robust, and relatively mature technology
  • Asia Pacific is expected to emerge as the fastest-growing regional market with a CAGR of 13.3% from 2022 to 2030, owing to developing economies such as India, South Korea, and China incorporating developments to sustain the competition

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Source
    • 1.1.3. End User
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1:
    • 1.9.2. Objective 2:
    • 1.9.3. Objective 3:
    • 1.9.4. Objective 4:

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Antibody Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Penetration & Growth Prospect Mapping
  • 3.2. Industry Value Chain Analysis
    • 3.2.1. Reimbursement framework
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
    • 3.3.3. Industry challenges
  • 3.4. Antibody Contract Manufacturing Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape
    • 3.4.3. Major Deals & Strategic Alliances Analysis
    • 3.4.4. Market Entry Strategies
    • 3.4.5. COVID-19 Analysis

Chapter 4. Antibody Contract Manufacturing Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Definitions and Scope
  • 4.3. Antibody Contract Manufacturing Market Share, 2021 & 2030
  • 4.4. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
    • 4.4.1. Monoclonal Antibodies
    • 4.4.2. Polyclonal Antibodies
    • 4.4.3. Others

Chapter 5. Antibody Contract Manufacturing Market: Source Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Definitions and Scope
  • 5.3. Antibody Contract Manufacturing Market Share, 2021 & 2030
  • 5.4. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
    • 5.4.1. Mammalian
    • 5.4.2. Microbial

Chapter 6. Antibody Contract Manufacturing Market: End User Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Definitions and Scope
  • 6.3. Antibody Contract Manufacturing Market Share, 2021 & 2030
  • 6.4. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
    • 6.4.1. Biopharmaceutical Companies
    • 6.4.2. Research Laboratories
    • 6.4.3. Others

Chapter 7. Antibody Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2021 & 2030
  • 7.3. Regional Market Share, 2020
  • 7.4. North America
    • 7.4.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Market estimates and forecast, 2017 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.5.2. U.K.
      • 7.5.2.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.5.6. Italy
      • 7.5.6.1. Market estimates and forecast, 2017 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Market estimates and forecast, 2017 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.7.4. Mexico
      • 7.7.4.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.7.5. Colombia
      • 7.7.5.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.7.6. Chile
      • 7.7.6.1. Market estimates and forecast, 2017 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.8.4. Egypt
      • 7.8.4.1. Market estimates and forecast, 2017 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
    • 8.1.1. Lonza
      • 8.1.1.1. Company overview
      • 8.1.1.2. Financial performance
      • 8.1.1.3. Product benchmarking
      • 8.1.1.4. Strategic initiatives
    • 8.1.2. Samsung Biologics
      • 8.1.2.1. Company overview
      • 8.1.2.2. Financial performance
      • 8.1.2.3. Product benchmarking
      • 8.1.2.4. Strategic initiatives
    • 8.1.3. WuXi Biologics.
      • 8.1.3.1. Company overview
      • 8.1.3.2. Financial performance
      • 8.1.3.3. Product benchmarking
      • 8.1.3.4. Strategic initiatives
    • 8.1.4. Charles River Laboratories
      • 8.1.4.1. Company overview
      • 8.1.4.2. Financial performance
      • 8.1.4.3. Product benchmarking
      • 8.1.4.4. Strategic initiatives
    • 8.1.5. FUJIFILM Holdings Corporation
      • 8.1.5.1. Company overview
      • 8.1.5.2. Financial performance
      • 8.1.5.3. Product benchmarking
      • 8.1.5.4. Strategic initiatives
    • 8.1.6. Boehringer Ingelheim Biopharmaceuticals GmbH.
      • 8.1.6.1. Company overview
      • 8.1.6.2. Financial performance
      • 8.1.6.3. Product benchmarking
      • 8.1.6.4. Strategic initiatives
    • 8.1.7. AGC Biologics
      • 8.1.7.1. Company overview
      • 8.1.7.2. Financial performance
      • 8.1.7.3. Product benchmarking
      • 8.1.7.4. Strategic initiatives
    • 8.1.8. Cytovance Biologics, Inc.
      • 8.1.8.1. Company overview
      • 8.1.8.2. Financial performance
      • 8.1.8.3. Product benchmarking
      • 8.1.8.4. Strategic initiatives
    • 8.1.9. EMERGENT
      • 8.1.9.1. Company overview
      • 8.1.9.2. Financial performance
      • 8.1.9.3. Product benchmarking
      • 8.1.9.4. Strategic initiatives
    • 8.1.10. Thermo Fisher Scientific
      • 8.1.10.1. Company overview
      • 8.1.10.2. Financial performance
      • 8.1.10.3. Product benchmarking
      • 8.1.10.4. Strategic initiatives
    • 8.1.11. Laboratory Corporation of America Holdings
      • 8.1.11.1. Company overview
      • 8.1.11.2. Financial performance
      • 8.1.11.3. Product benchmarking
      • 8.1.11.4. Strategic initiatives
    • 8.1.12. Catalent, Inc
      • 8.1.12.1. Company overview
      • 8.1.12.2. Financial performance
      • 8.1.12.3. Product benchmarking
      • 8.1.12.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 List of Secondary Sources
  • Table 3 Global Antibody Contract Manufacturing Market, by Region 2017 - 2030 (USD Million)
  • Table 4 Global Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 5 Global Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 6 Global Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 7 North America Antibody Contract Manufacturing Market, by Country, 2017 - 2030 (USD Million)
  • Table 8 North America Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 9 North America Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 10 North America Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 11 U.S. Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 12 U.S. Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 13 U.S. Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 14 Canada Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 15 Canada Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 16 Canada Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 17 Europe Antibody Contract Manufacturing Market, by Country, 2017 - 2030 (USD Million)
  • Table 18 Europe Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 19 Europe Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 20 Europe Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 21 U.K. Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 22 U.K. Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 23 U.K. Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 24 Germany Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 25 Germany Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 26 Germany Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 27 France Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 28 France Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 29 France Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 30 Italy Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 31 Italy Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 32 Italy Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 33 Spain Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 34 Spain Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 35 Spain Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 36 Asia Pacific Antibody Contract Manufacturing Market, by Country, 2017 - 2030 (USD Million)
  • Table 37 Asia Pacific Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 38 Asia Pacific Discovery Outsourcing Market, by Source, 2017 - 2030 (USD Million)
  • Table 39 Asia Pacific Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 40 Japan Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 41 Japan Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 42 Japan Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 43 China Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 44 China Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 45 China Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 46 India Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 47 India Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 48 India Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 49 Australia Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 50 Australia Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 51 Australia Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 52 South Korea Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 53 South Korea Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 54 South Korea Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 55 Latin America Antibody Contract Manufacturing Market, by Country, 2017 - 2030 (USD Million)
  • Table 56 Latin America Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 57 Latin America Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 58 Latin America Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 59 Brazil Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 60 Brazil Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 61 Brazil Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 62 Mexico Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 63 Mexico Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 64 Mexico Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 65 Argentina Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 66 Argentina Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 67 Argentina Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 68 Colombia Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 69 Colombia Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 70 Colombia Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 71 Chile Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 72 Chile Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 73 Chile Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 74 MEA Antibody Contract Manufacturing Market, by Country, 2017 - 2030 (USD Million)
  • Table 75 MEA Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 76 MEA Antibody Contract Manufacturing Market, by Source, 2017 - 2030 (USD Million)
  • Table 77 MEA Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 78 South Africa Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 79 South Africa Discovery Outsourcing Market, by Source, 2017 - 2030 (USD Million)
  • Table 80 South Africa Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 81 UAE Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 82 UAE Discovery Outsourcing Market, by Source, 2017 - 2030 (USD Million)
  • Table 83 UAE Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)
  • Table 84 Egypt Antibody Contract Manufacturing Market, by Product, 2017 - 2030 (USD Million)
  • Table 85 Egypt Discovery Outsourcing Market, by Source, 2017 - 2030 (USD Million)
  • Table 86 Egypt Antibody Contract Manufacturing Market, by End User, 2017 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Antibody Contract Manufacturing market: Market snapshot
  • Fig. 9 Antibody Contract Manufacturing market: Market segmentation
  • Fig. 10 Antibody Contract Manufacturing market: Strategy framework
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Antibody Contract Manufacturing market driver impact
  • Fig. 14 Antibody Contract Manufacturing market restraint impact
  • Fig. 15 Antibody Contract Manufacturing market porter's five forces analysis
  • Fig. 16 Antibody Contract Manufacturing market PESTEL analysis
  • Fig. 17 Antibody Contract Manufacturing market segment dashboard
  • Fig. 18 Antibody Contract Manufacturing market: Product movement Analysis
  • Fig. 19 Monoclonal Antibodies Antibody Contract Manufacturing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 20 Polyclonal Antibodies Antibody Contract Manufacturing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 21 Others Antibody Contract Manufacturing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 22 Antibody Contract Manufacturing market segment dashboard
  • Fig. 23 Mammalian Antibody Contract Manufacturing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 24 Microbial Antibody Contract Manufacturing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 25 Global Antibody Contract Manufacturing market: Regional movement analysis
  • Fig. 26 Global market share, by region
  • Fig. 27 North America market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 28 U.S. market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 29 Canada market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 30 Europe market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 31 U.K. market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 32 Germany market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 33 France market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 34 Italy market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 35 Spain market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 36 Asia Pacific market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 37 Japan market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 38 China market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 39 India market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 40 Australia market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 41 South Korea market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 42 Latin America market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 43 Brazil market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 44 Mexico market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 45 Argentina market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 46 Colombia market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 47 Chile market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 48 Middle East and Africa market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 49 South Africa market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 50 UAE market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 51 Egypt market estimates and forecast, 2017 - 2030 (USD Million)